UConn selects Medable platform to study adverse digital trial events
The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare has selected digital trials platform provider Medable’s Cloud-based platform to study statin-related adverse events.
Amgen therapy improves diastolic function in heart failure with reduced ejection fraction
The COSMIC-HF trial looked at the effects of omecamtiv mecarbil in patients with stable but symptomatic heart failure.
Boehringer Ingleheim’s Jardiance set to compete as a new therapy for heart failure
Boehringer Ingelheim and Eli Lilly post their trial results at the American Heart Association Scientific Sessions 2019.
DAPA-HF blazing a trail for sodium-glucose co-transporter-2 inhibitors in heart failure
Phase III trial looked at the outcomes of AstraZeneca’s Farxiga use in patients with heart failure with reduced ejection fraction, in patients both with and without diabetes.
Merck says vericiguat’s VICTORIA trial met primary endpoint
Merck has reported that the Phase III VICTORIA clinical trial of vericiguat met its primary efficacy endpoint in patients suffering from worsening chronic heart failure with reduced ejection fraction (HFrEF).
Janssen reimagines digital clinical trial design with CHIEF-HF
The Janssen Pharmaceutical Companies of Johnson & Johnson is reimagining digital clinical trial design with the launch of a new study.
Amgen’s Repatha reduces CV events risk in FOURIER trial
Amgen has reported new data from the cardiovascular outcomes FOURIER study of Repatha (evolocumab) in patients who have experienced a recent myocardial infarction (MI) or heart attack.
Coronary artery disease clinical trials characterised by high completion rate over 10 years
3D illustration: For those with coronary artery disease, blocking of the arteries is caused by the formation of plaques (cholesterol deposits) inside the arteries,
Lilly and Boehringer begin study of Jardiance in heart failure
Eli Lilly and Boehringer Ingelheim have started a Phase III clinical trial, EMPULSE, to evaluate whether Jardiance (empagliflozin) improves acute heart failure.